Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.

Overview

Biolab Sanus is developing a product in the form of orodispersible tablet containing 1.0 mg, 1.75 mg and 3.5 mg of Zolpidem®. Thus, it is intended to evaluate the efficacy of Zolpidem® Orodispersible 1.0 mg or 1.75 mg in women and Zolpidem Orodispersible 1.75 mg or 3.5 mg in men for the improvement of the maintenance insomnia disorder, through the evaluation of the Insomnia Severity Index, and using a Sleep Diary throughout the study, as well as to evaluate the latency of the sleep after a spontaneous or provoked wake up measured by polysomnography.

Full Title of Study: “Phase II / III Study, One Center, Double-Blind, With Placebo Use, in Parallel Groups to Assess the Efficacy and Safety of Zolpidem® Orodispersible in Adult Subjects (Females and Males) in the Treatment of Maintenance Insomnia Disorder.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2021

Detailed Description

Information provided evidence for the therapeutic use of Zolpidem® in the treatment of insomnia. Several studies have emphasized the importance of using Zolpidem® in small doses, in the orodispersible form, in the treatment of insomnia. Accordingly, Biolab Sanus is developing a product in the form of orodispersible tablet containing 1.0 mg, 1.75 mg and 3.5 mg of Zolpidem®. Thus, it is intended to evaluate the efficacy of Zolpidem® Orodispersible 1.0 mg or 1.75 mg in women and Zolpidem Orodispersible 1.75 mg or 3.5 mg in men for the improvement of the maintenance insomnia disorder, through the evaluation of the Insomnia Severity Index, and using a Sleep Diary throughout the study, as well as to evaluate the latency of the sleep after a spontaneous or provoked wake up measured by polysomnography.

Interventions

  • Drug: Zolpidem
    • Zolpidem or Placebo if there is a wake up during the night

Arms, Groups and Cohorts

  • Placebo Comparator: Men – Placebo
    • Men – Placebo, 1 tablet if a wake up occurs
  • Experimental: Men – Zolpidem 1.75 mg
    • Men – Zolpidem 1.75 mg, 1 tablet if a wake up occurs
  • Experimental: Men – Zolpidem 3.5 mg
    • Men – Zolpidem 3.5 mg, 1 tablet if a wake up occurs
  • Placebo Comparator: Women – Placebo
    • Women – Placebo, 1 tablet if a wake up occurs
  • Experimental: Women – Zolpidem 1.0 mg
    • Women – Zolpidem 1.0 mg, 1 tablet if a wake up occurs
  • Experimental: Women – Zolpidem 1.75 mg
    • Women – Zolpidem 1.75 mg, 1 tablet if a wake up occurs

Clinical Trial Outcome Measures

Primary Measures

  • Difference Insomnia Severity Index (ISI) as assessed by questionnaire before treatment and after the treatment
    • Time Frame: 28 days
    • To analyse the efficacy of Zolpidem® Orodispersible treatment 1.0 mg or 1.75 mg in women and 1.75 mg and 3.5 mg in men, compared to placebo, after taking the medication when a spontaneous wake up occurs during 28 days. The assessement will be performed by means of the standard questionnaire before and at the end of the treatment period. The computed mean difference for each treatment will be compared by ANOVA (treatment doses vs placebo in each gender) in order to assess its statistical significance.

Secondary Measures

  • Total Sleep Time (polysomnography parameter)
    • Time Frame: 1 day
    • Total Sleep Time after a provoked wake up, and the administration of 1 tablet of Zolpidem® Orodispersible 1.0 mg or 1.75 mg in women and 1.75 mg or 3.5 mg in men, as compared to placebo administration after a provoked wake up.
  • Sleep Efficiency (polysomnography parameter)
    • Time Frame: 1 day
    • Sleep Efficiency after a provoked wake up, and the administration of 1 tablet of Zolpidem® Orodispersible 1.0 mg or 1.75 mg in women and 1.75 mg or 3.5 mg in men, as compared to placebo administration after a provoked wake up.
  • Sleep Latency (polysomnography parameter)
    • Time Frame: 1 day
    • Sleep Latency after a provoked wake up, and the administration of 1 tablet of Zolpidem® Orodispersible 1.0 mg or 1.75 mg in women and 1.75 mg or 3.5 mg in men, as compared to placebo administration after a provoked wake up.

Participating in This Clinical Trial

Inclusion Criteria

1. Men and women ≥ 18 years and ≤ 64 years of age 2. Participants willing and able to provide a written informed consent form, after an explanation of the nature of the study, and prior to any procedures related to the study. 3. Adults with clinical diagnosis of insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V-TR) and who complain of difficulty in maintaining sleep, starting more than three months before the study initiation, and for three or more sleepless nights per week. 4. Participants with ability to understand and willingness to comply with the study procedures Exclusion Criteria:

1. History of Allergy or Hypersensitivity to Zolpidem; 2. All initial and secondary insomnia; 3. Basal polysomnography with apnea and hypopnea index> 20 events / hour and PLM (Periodic Leg Movements)> 15 events / hour. 4. Participants who used central nervous system medication or other medication known to interfere with the sleep / wake up cycle within 15 days prior to enrollment in the study, at the discretion of the study investigator. 5. Clinically significant diseases or surgeries, at the discretion of the principal investigator, within 30 days prior to study inclusion. 6. History of chemical dependence or alcohol abuse. 7. Any significant neurological and psychiatric disease or laboratory findings present, unless adequately controlled with medication allowed in the protocol. 8. Participants who received any investigational medication in the last 12 months prior to study inclusion. 9. Women who are pregnant or breastfeeding or who wish to become pregnant or who refuse to use safe contraceptive methods during the study. 10. Any disorder of the circadian cycle. 11. Regular night shift work within the last 2 weeks prior to study enrollment or expected to work in shifts during the study.

Gender Eligibility: All

Men: Placebo or Zolpidem 1.75 mg or Zolpidem 3.5 mg Women: Placebo or Zolpidem 1.0 mg or Zolpidem 1.75 mg

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Biolab Sanus Farmaceutica
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Luciano R Pinto Junior, PhD, 55.11.973342037, lucianoribeiro48@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.